Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  The Lancet Oncology

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(05)70176-5PMID 15925816
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

  2005cited by this paper
• Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

  2005cited by this paper
• Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer.

  2005cited by this paper
• Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

  2004cited by this paper
• HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer

  2004cited by this paper
• Primary chemotherapy for breast cancer: the evidence and the future.

  2004cited by this paper
• Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

  2004cited by this paper
• Phospho-Serine-118 Estrogen Receptor-α Expression Is Associated with Better Disease Outcome in Women Treated with Tamoxifen

  2004cited by this paper
• Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

  2004cited by this paper
• Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.

  2004cited by this paper
• Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.

  2004cited by this paper
• Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy

  2004cited by this paper
• A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

  2004cited by this paper
• First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

  2004cited by this paper
• Biological markers during early treatment of tamoxifen resistant breast cancer with gefitinib ('Iressa')[Abstract]

  2004cited by this paper
• ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.

  2003cited by this paper
• Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

  2003cited by this paper
• International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

  2003cited by this paper
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  2002cited by this paper
• Endocrine-responsive breast cancer and strategies for combating resistance

  2002cited by this paper
• Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

  2000cited by this paper
• Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance

  2000cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

  1997cited by this paper
• Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.

  1996cited by this paper
• Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.

  1996cited by this paper
• Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

  1996cited by this paper
• Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase

  1995cited by this paper
• Crystal structure of the tyrosine kinase domain of the human insulin receptor

  1994cited by this paper
• Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region.

  1993cited by this paper
• The when and how of Src regulation.

  1993cited by this paper
• The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

  1992cited by this paper
• Immunocytochemical determination of epidermal growth factor receptor with monoclonal EGFR1 antibody in primary breast cancer patients.

  1990cited by this paper
• Evaluation of epidermal growth factor receptor occupency by EGF-like peptide in 55 breast and 42 non breast tumor biopsies

  1990cited by this paper
• Immunoproliferative small-intestinal disease. An immunohistochemical study.

  1989cited by this paper
• Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study.

  1988cited by this paper
• Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

  1987cited by this paper
• Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

  1985cited by this paper

• Why Does EGFR-Targeted Therapy Continue to Fail in Breast Cancer? From Mechanistic Deciphering to Novel Intervention Strategies.

  2026cites this paper
• Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention

  2025cites this paper
• Role of imaging based response assesment for adapting neoadjuvant systemic therapy for breast cancer: A systematic review.

  2025cites this paper
• MMSyn: A New Multimodal Deep Learning Framework for Enhanced Prediction of Synergistic Drug Combinations

  2024cites this paper
• PRIMARY PREVENTION AND INTERCEPTION STUDIES IN RAS-MUTATED TUMOR MODELS EMPLOYING SMALL MOLECULES OR VACCINES.

  2023cites this paper
• A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer

  2023cites this paper
• Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action

  2023cites this paper
• Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker

  2022cites this paper
• Unconventional protein post-translational modifications: the helmsmen in breast cancer

  2022cites this paper
• Tyrosine kinase inhibitors in breast cancer (Review).

  2021influential citation
• The efficacy of gefitinib supplementation for breast cancer

  2020cites this paper
• A meta-analysis of randomized controlled studies

  2019cites this paper
• EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.

  2019cites this paper
• Neoadjuvant Hormonal Therapy in Breast Cancer

  2019cites this paper
• Tyrosine Kinase Inhibitors

  2019cites this paper
• Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers

  2019cites this paper
• Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor‐positive breast cancer: A network meta‐analysis

  2019influential citation
• Title: Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically-Induced Cancers

  2019cites this paper
• Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line.

  2019cites this paper
• Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

  2019cites this paper
• Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models

  2018cites this paper
• Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression

  2018cites this paper
• Afatinib and Erlotinib in the treatment of squamous-cell lung cancer

  2018cites this paper
• ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer

  2018cites this paper
• Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis

  2017cites this paper
• TARGETING AUTOPHAGY TO IMPROVE EFFICACY OF CDK4/6 INHIBITION IN BREAST CANCER

  2017cites this paper
• Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer

  2017cites this paper
• Reply to R.F. Sweis et al.

  2017cites this paper
• Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation

  2016cites this paper
• Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer

  2016cites this paper
• Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

  2016cites this paper
• Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.

  2016cites this paper
• A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).

  2016cites this paper
• Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer.

  2016cites this paper
• Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential

  2016cites this paper
• Resistance to Targeted Therapies in Breast Cancer.

  2016cites this paper
• The scaffolding protein NHERF 1 sensitizes EGFR-dependent tumor growth , motility and invadopodia function to gefitinib treatment in breast cancer cells

  2015cites this paper
• Triple positive breast cancer: a distinct subtype?

  2015cites this paper
• Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

  2015cites this paper
• Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

  2015cites this paper
• Early Surrogate Markers of Treatment Activity: Where Are We Now?

  2015cites this paper
• The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.

  2015cites this paper
• Incidence and risk of xerosis with targeted anticancer therapies.

  2015cites this paper
• Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer.

  2015cites this paper
• Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review

  2015influential citation
• Optimizing the Use of Neoadjuvant Endocrine Therapy

  2015cites this paper
• Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.

  2014cites this paper
• Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease

  2014cites this paper
• Successes and limitations of targeted cancer therapy in breast cancer.

  2014cites this paper
• Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

  2014cites this paper
• Emerging EGFR antagonists for breast cancer

  2014cites this paper
• Breast cancer: Current and future endocrine therapies

  2014cites this paper
• Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

  2014cites this paper
• Biomarkers of drugs targeting HER‐family signalling in cancer

  2014cites this paper
• EFFECT OF INTERMITTENT DOSING REGIMENS OF ERLOTINIB ON METHYLNITROSOUREA-INDUCED MAMMARY CARCINOGENESIS An uninvited scientific article Contract Support: National Cancer Institute, Contract Number HHSN261200433001C

  2013cites this paper
• Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis

  2013cites this paper
• An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).

  2013cites this paper
• Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.

  2013cites this paper
• Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845

  2013cites this paper
• Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.

  2013cites this paper
• The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study

  2013cites this paper
• Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy.

  2013cites this paper
• An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma

  2012cites this paper
• Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

  2012cites this paper
• Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers

  2012cites this paper
• New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance.

  2012cites this paper
• Promise and failure of targeted therapy in breast cancer.

  2012cites this paper
• ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

  2012cites this paper
• Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells

  2012cites this paper
• Targeted Nanoparticles for Cancer Therapy

  2012cites this paper
• The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

  2012cites this paper
• Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer

  2012cites this paper
• Targeted therapies in breast cancer: are heart and vessels also being targeted?

  2012cites this paper
• Role of epidermal growth factor receptor in breast cancer

  2012cites this paper
• An update on chemotherapy and tumor gene expression profiles in breast cancer

  2012cites this paper
• Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.

  2012cites this paper
• Targeting the subtypes of breast cancer: rethinking investigational drugs

  2012cites this paper
• Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

  2012cites this paper
• Neoadjuvant therapy in early-stage breast cancer.

  2012cites this paper
• Mechanisms of endocrine resistance in breast cancer.

  2011cites this paper
• The Clinical Pharmacology of Anastrozole

  2011cites this paper
• The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy.

  2011cites this paper
• Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance

  2011cites this paper
• A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative.

  2011cites this paper
• Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

  2011cites this paper
• The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway

  2011cites this paper
• Biological mechanisms and clinical implications of endocrine resistance in breast cancer.

  2011cites this paper
• Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk

  2011cites this paper
• A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

  2011cites this paper
• Antiangiogenic strategies in breast cancer management.

  2010cites this paper
• A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer

  2010cites this paper
• Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer

  2010cites this paper
• New Strategies in Estrogen Receptor–Positive Breast Cancer

  2010cites this paper
• Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo

  2010cites this paper
• Neoadjuvant endocrine therapy for breast cancer.

  2010cites this paper
• Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

  2010cites this paper
• Hormone-biological therapy in breast cancer: preclinical evidences, clinical studies and future directions.

  2010cites this paper
• Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

  2010cites this paper
• Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer

  2010cites this paper
• Angiogenesis in Breast Cancer: Molecular Markers, Therapeutic Targets, Antiangiogenic Therapy & Inhibitors

  2010cites this paper